Galectin-3 exacerbates autoimmune diabetes by limiting regulatory T cell differentiation and function.

Summary

T1D patients and their first-degree relatives exhibit elevated serum galectin-3, largely from monocytes/macrophages. Both pharmacologic inhibition (TD139) and genetic deletion mitigated galectin-3–mediated suppression of regulatory T cells, identifying a mechanistic axis that may be therapeutically tractable.

Key Findings

• Serum galectin-3 levels were significantly elevated in T1D patients and their first-degree relatives compared with healthy controls.
• Monocytes/macrophages were identified as the main source of circulating galectin-3.
• Pharmacologic inhibition with TD139 and galectin-3 gene knockout attenuated galectin-3–mediated suppression of regulatory T cells.

Clinical Implications

Galectin-3 may serve as a biomarker for at-risk individuals (including first-degree relatives) and a therapeutic target; clinical trials of galectin-3 inhibition (e.g., TD139) in T1D prevention or modulation warrant consideration.

Limitations

• Sample size and detailed cohort characteristics are not provided in the abstract.
• Cross-sectional human comparisons limit causal inference; translational efficacy in patients remains to be tested.

Future Directions

Prospective studies testing galectin-3 inhibition in at-risk relatives or recent-onset T1D, alongside validation of galectin-3 as a predictive biomarker.